Projecting the Potential Cost Effectiveness of Ocrelizumab Versus Standard Care in Primary Progressive Multiple Sclerosis Patients Under Alternative Pricing Scenarios
May 1, 2016, 00:00 AM
10.1016/j.jval.2016.03.200
https://www.valueinhealthjournal.com/article/S1098-3015(16)00268-0/fulltext
Section Title :
Neurological Disorders - Cost Studies
Section Order :
1535
First Page :
A62
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)00268-0&doi=10.1016/j.jval.2016.03.200